Medtronic Consent Decree Halts Routine Sales Of Synchromed II Pump

Medtronic and its CEO S. Omar Ishrak and Medtronic Neuro President Thomas M. Tefft entered into a consent decree with FDA over quality system violations for its Synchromed II infusion pumps, and must stop making, designing and distributing them except when medically necessary.

Medtronic PLC has been ordered to stop making and distributing the Synchromed II implantable infusion pumps except in limited circumstances until the company corrects quality system violations in a complaint and consent decree between FDA and the firm, filed in U.S. District Court April 27.

The consent decree names the company and CEO S. Omar Ishrak and Medtronic Neuro President Thomas M. Tefft for violations...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Policy & Regulation

MDUFA VI Launches With Public Meeting, Call For Comments

 
• By 

Preparations for the reauthorization of the Medical Device User Fee Amendments for 2028-2032 are underway, with the US FDA announcing a public meeting for 4 August. After negotiations with industry and other stakeholders, a draft agreement is due to Congress by 15 January 2025.

Permanent FDA Top Lawyer Expected After HHS Counsel Confirmation

 
• By 

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.

FDA Drops Package Labeling Guidance For Hernia Mesh Manufacturers

 

The US FDA recently published a draft guidance document for manufacturers of mesh products that are used during several types of hernia repair procedures.